Safety, Tolerability, and Pharmacokinetics of ANX1502 in Primary Cold Agglutinin Disease: A Phase 1b, Open-Label, Single-Arm Study

The primary objective of this study is to evaluate the **safety** and **tolerability** of ANX1502 in participants with **Primary Cold Agglutinin Disease (CAD)**. This is clinically relevant as CAD is a rare autoimmune hemolytic anemia characterized by the presence of cold-reacting autoantibodies, leading to hemolysis and anemia. Understanding the safety profile of ANX1502 is crucial for determining its potential as a therapeutic option for managing CAD.

The clinical trial involves participants diagnosed with **Primary Cold Agglutinin Disease (CAD)**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population, as well as any specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed as a **Phase 1b**, open-label, single-arm study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical effect of ANX1502 in participants diagnosed with **Primary Cold Agglutinin Disease (CAD)**. The trial is scheduled to commence recruitment on April 15, 2024, and is expected to conclude by September 30, 2025. Participants will be involved in the study for the duration of the trial, with specific timelines for individual involvement determined by the study protocol.

The trial will begin with an inclusion (screening) visit, where potential participants will be assessed for eligibility based on predefined criteria. This visit aims to ensure that only suitable candidates are enrolled in the study. Following successful screening, participants will undergo a series of study visits, each designed to monitor their response to the investigational product and assess various safety and efficacy parameters. These visits will include regular follow-up assessments to track the progress and any adverse effects experienced by the participants.

The end-of-study visit will mark the conclusion of a participant's involvement in the trial. During this visit, final evaluations will be conducted to gather comprehensive data on the long-term effects of the treatment. Participants may be withdrawn from the study prior to its completion if they experience significant adverse events, fail to comply with study procedures, or withdraw consent. The study's design and procedures are structured to ensure the collection of robust data while maintaining participant safety and adherence to ethical standards.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on April 15, 2024, with an estimated completion date of September 30, 2025. Efficacy will be evaluated using predefined primary and secondary endpoints, although specific parameters or endpoints are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for assessment, are not specified in the available information. The trial's focus is on obtaining robust efficacy data to support the therapeutic claims of the investigational product.